Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Adenocarcinoma × ipatasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Recurrence 1 Prostatic Neoplasms 1 Neoplasms, Unknown Primary 1 Mouth Neoplasms 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Carcinoma 1 Adenocarcinoma 1

Interventions

Oxaliplatin 26 Gemcitabine 22 Fluorouracil 17 Capecitabine 16 Leucovorin 15 pembrolizumab 14 Docetaxel 13 Cisplatin 13 Bevacizumab 12 Radiotherapy 8 Paclitaxel 7 Irinotecan 7 Trastuzumab 6 Pemetrexed 6 Carboplatin 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 cemiplimab 5 Sunitinib 4 Metformin 4 Gefitinib 4 Erlotinib Hydrochloride 4 trastuzumab deruxtecan 3 tislelizumab 3 cabozantinib 3 atezolizumab 3 Taxes 3 Sorafenib 3 Ramucirumab 3 Nivolumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04739202 2021-03-29

IMMUNOGAST

Hospices Civils de Lyon

Phase 2 Unknown

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡